Richard Mark Kirkner

2 weeks ago | medscape.com | Richard Mark Kirkner

Advocates for eye and vision research must come together now to thwart attempts by the Trump administration to slash research funding and downgrade and dilute the National Eye Institute (NEI) of the National Institutes of Health (NIH), researchers and clinical trial investigators were told at the Association for Research in Vision and Ophthalmology (ARVO) 2025 Annual Meeting.

2 weeks ago | medscape.com | Richard Mark Kirkner

In the 11 years since it was approved for the treatment of melanoma, pembrolizumab (Keytruda) has become the go-to for adjuvant or neoadjuvant therapy for advanced melanoma, despite the potential for side effects, which can be severe and occur in more than half of all patients. Oncologists need to weigh the risk of those side effects against the strong evidence supporting the effectiveness of pembrolizumab to improve survival.

1 month ago | managedhealthcareexecutive.com | Richard Mark Kirkner

People who have severe aortic stenosis but who have a low risk of mortality from surgery do just as well with transcatheter aortic valve replacement (TAVR) as they do with the surgical approach, although the less invasive procedure did provide some slight advantages over a five-year period, results of a randomized clinical trial demonstrated. The results were presented at the American College of Cardiology Annual Scientific Session and Expo and published in JACC.

1 month ago | managedhealthcareexecutive.com | Richard Mark Kirkner

Bentracimab, a monoclonal antibody administered intravenously, can be an effective agent to quickly reverse the effects of the antiplatelet agent Brilinta (ticagrelor) in patients who need to have urgent surgery or who are having major bleeding, a study presented at the American College of Cardiology’s annual scientific session found.

2 months ago | managedhealthcareexecutive.com | Richard Mark Kirkner

The glucagon-like peptide 1 (GLP1) receptor agonist semaglutide significantly improved cardiovascular function and walking endurance, along with other quality-of-life measures, after one year in people with peripheral artery disease (PAD) and type 2 diabetes, according to results of a multinational phase 3b trial presented at the American College of Cardiology Scientific Session today in Chicago.